About Us Resources Papers Brochures Infographics Posters Papers Videos & Webinars Plasmid Finder PAPERS A selection of flyers with data and highlights of some of our services and technologies at OXGENE Easy to digest data and information on our technologies and solutions at OXGENE This is our library of scientific posters that has been carefully created and curated by our amazing scientists at OXGENE This is our library of published papers from our select staff at OXGENE View our curated collection of videos and past webinars Breaking The Gene Therapy Bottlenecks OXGENE Editorial /Pharma Intelligence /02 October 2021 Insights into how to overcome common hurdles to manufacturing and developing gene therapy, including overcoming a reliance on plasmid technology, streamlining manufacturing processing, and more. Accelerating the Clinical Success of Gene Therapies through Viral Vector Engineering OXGENE Sponsored/GEN /01 September 2021/Issue Issuer Vol. 41, Issue 9 Viruses have evolved to invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genomes. While these properties make viruses dangerous pathogens, they also make them ideal couriers for getting new DNA into a host cell... Viral vector engineering to improve clinical performance and accelerate timelines for novel gene therapies Sophie Lutter Editorial /Manufacturing Chemist /13 August 2021 Viruses invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genome. This makes them dangerous pathogens as well as ideal couriers to transport new DNA into a host cell and ensure that it’s transcribed, reports Dr... Viral vector engineering to improve clinical performance & accelerate timelines for novel therapies OXGENE Editorial/Manufacturing Chemist/13 August 2021 Advanced therapy manufacturers have taken the head start that Nature’s given them and used developments in genetic engineering, computational biology and bioinformatics to perfect the viral particle as a vector for therapeutic DNA and hasten the clinical success of... Revving the engine of CAR-T development Sophie Lutter White Paper/TheScientist/14 July 2021 CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are racing to break through the barrier of solid tumours, taking imaginative approaches to overcome the numerous... Are We Nearly There Yet? The Ongoing Journey of CAR T Cell Therapies Sophie Lutter Editorial/European Biopharmaceutical Review/01 July 2021 CAR T cell therapies have been met by numerous scientific, logistical, and manufacturing challenges, and yet, a shared determination to produce readily available, cost-effective CAR T cell therapies is more present than ever. Antibody therapeutics: the other race for immunity against SARS-CoV2 Sophie Lutter Editorial/Drug Discovery World/05 May 2021/Issue Vol. 22, Issue 2 Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19... Identifying Antibodies that Target Membrane Proteins in Their Native Conformations OXGENE Sponsored/TheScientist/10 March 2021 A new mammalian display platform enhances antibody discovery for challenging protein targets. Membrane proteins are important therapeutic targets as they transduce signals into cells, transport molecules, bind to surfaces, and catalyze reactions. However, researchers... Optimizing Adeno-Associated Virus (AAV) Manufacturing OXGENE Sponsored/TheScientist/16 February 2021 Viral vices have been center stage throughout the ongoing pandemic, but to the everyday scientist, viruses are essential tools in the research toolbox. Viruses are vectors not of disease, but of gene-edited transcripts, candidate genes, and potential therapeutics. These... Affinity maturation of a GPCR binder using OXGENE’s novel self-labelling antibody discovery platform OXGENE Editorial/Drug Discovery World/28 January 2021/Issue Vol. 22, Issue 1 Identification and affinity maturation of antibodies against membrane proteins in their native configuration remains challenging. Here, OXGENE use their SLIM display antibody discovery platform for a affinity maturation project using a parental antibody against a GPCR... 1234